You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • AB0060 Adalimumab is more effective than etanercept or abatacept at inhibiting tnf-enhanced human osteoclast development under in vitro conditions of chronic tnf exposure

Alerts

Article menu
Download PDFPDF
Abstracts accepted for publication
Cartilage, synovium and osteoimmunology
AB0060 Adalimumab is more effective than etanercept or abatacept at inhibiting tnf-enhanced human osteoclast development under in vitro conditions of chronic tnf exposure
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address